Cephalon Announces Positive Results From A Phase Three Study Of NUVIGIL In Jet Lag Disorder
Cephalon, Inc. (NASDAQ: CEPH) announced positive results from a phase three clinical trial of NUVIGIL® (armodafinil) Tablets [C-IV] as a treatment for excessive sleepiness associated with jet lag disorder. Based on these findings, Cephalon® will file a supplemental New Drug Application with the U.S. Food and Drug Administration to expand the indications for NUVIGIL during the third quarter of this year.
More: continued here
Filed under: Endocrinology on April 10th, 2009
You must be logged in to post a comment.